PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs

PURPOSE: We provide a comparison between 22C3 pharmDx and SP263 assay, for evaluating programmed death ligand 1 (PD-L1) expression in advanced gastric cancer (GC) patients. MATERIALS AND METHODS: The PD-L1 immunohistochemistry by 22C3 pharmDx and SP263 assays was performed in the center of the tumor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res Treat
Autores principales: Park, Yujun, Koh, Jiwon, Na, Hee Young, Kwak, Yoonjin, Lee, Keun-Wook, Ahn, Sang-Hoon, Park, Do Joong, Kim, Hyung-Ho, Lee, Hye Seung
Formato: Artigo
Lenguaje:Inglês
Publicado: Korean Cancer Association 2020
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7373862/
https://ncbi.nlm.nih.gov/pubmed/32019283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2019.718
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares